1. | oxbum49791 | |
2. | latinoboyz4874 | |
3. | MamisTrist | |
4. | rpereira07 | |
5. | boxerrunner27 |
1. | oxbum49791 | |
2. | latinoboyz4874 | |
3. | MamisTrist | |
4. | rpereira07 | |
5. | boxerrunner27 |
1. | WalkingDeader 01/22/2018 Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period |
2. | 813kimd 02/18/2018 Novartis AG is preparing to sell its U.S. generic pill business, |
3. | sonhinchie 04/10/2018 Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader |
4. | WalkingDeader 01/26/2018 UPGRADES SOON - Reports of EPS beat ranging from $0.02 to $0.04. Beats on revenues. |
5. | sonhinchie 05/15/2018 Novartis completes tender offer for all outstanding shares of AveXis, Inc. |
6. | oxbum49791 01/18/2018 Superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients |
7. | rpereira07 01/25/2018 Wow!! ... More Awesome news for $NVS |
8. | MamisTrist 01/22/2018 Good stuff! |
9. | 813kimd 03/27/2018 Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities |
10. | boxerrunner27 03/26/2018 Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS |